Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.

Sud S, Mittmann N, Cook DJ, Geerts W, Chan B, Dodek P, Gould MK, Guyatt G, Arabi Y, Fowler RA; Canadian Critical Care Trials Group; E-PROTECT Investigators.

Am J Respir Crit Care Med. 2011 Dec 1;184(11):1289-98. doi: 10.1164/rccm.201106-1059OC. Epub 2011 Aug 25.

PMID:
21868500
2.

An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding.

Chiasson TC, Manns BJ, Stelfox HT.

PLoS Med. 2009 Jun 23;6(6):e1000098. doi: 10.1371/journal.pmed.1000098. Epub 2009 Jun 23.

3.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
4.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

5.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
6.

A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.

Lynd LD, Goeree R, Crowther MA, O'Brien BJ.

Can J Clin Pharmacol. 2007 Summer;14(2):e215-26. Epub 2007 Jun 6.

PMID:
17652767
7.

Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis.

Nguyen GC, Sharma S.

Inflamm Bowel Dis. 2013 Sep;19(10):2182-9. doi: 10.1097/MIB.0b013e31829c01ef.

PMID:
23883960
8.

Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.

Dranitsaris G, Stumpo C, Smith R, Bartle W.

Am J Cardiovasc Drugs. 2009;9(1):45-58. doi: 10.2165/00129784-200909010-00005.

PMID:
19178131
9.

Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

McCullagh L, Walsh C, Barry M.

Pharmacoeconomics. 2012 Oct 1;30(10):941-59. doi: 10.2165/11591510-000000000-00000.

PMID:
22667458
10.

Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.

Fowler RA, Mittmann N, Geerts WH, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

Trials. 2014 Dec 20;15:502. doi: 10.1186/1745-6215-15-502.

11.

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.

Wilbur K, Lynd LD, Sadatsafavi M.

Clin Appl Thromb Hemost. 2011 Oct;17(5):454-65. doi: 10.1177/1076029610376935. Epub 2010 Aug 10.

PMID:
20699258
12.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
13.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

14.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
16.
17.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

18.

Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.

Johnston JA, Brill-Edwards P, Ginsberg JS, Pauker SG, Eckman MH.

Am J Med. 2005 May;118(5):503-14. Review.

PMID:
15866253
19.

Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.

Shorr AF, Ramage AS.

Crit Care Med. 2001 Sep;29(9):1659-65.

PMID:
11546959
20.

Supplemental Content

Support Center